ORKAMBI Market

“ORKAMBI Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about ORKAMBI for Cystic Fibrosis in the six major markets. A detailed picture of the ORKAMBI for cystic fibrosis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this report along with a detailed description of the ORKAMBI for cystic fibrosis. The report provides insights about ORKAMBI mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ORKAMBI market forecast analysis for cystic fibrosis in the 6MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in cystic fibrosis.

ORKAMBI Drug Summary

ORKAMBI is a combination of lumacaftor and ivacaftor, CFTR potentiator, indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. Moreover, the efficacy and safety of ORKAMBI have not been established in Cystic Fibrosis Patients other than those homozygous for the F508del mutation.

The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. The F508del mutation results in protein misfolding, causing a defect in cellular processing and trafficking that targets the protein for degradation and therefore reduces the quantity of CFTR at the cell surface. The small amount of F508del-CFTR that reaches the cell surface is less stable and has low channel-open probability (defective gating activity) compared to wild-type CFTR protein. Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and trafficking of mature protein to the cell surface.

Furthermore, ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface. In vitro studies have demonstrated that both lumacaftor and ivacaftor act directly on the CFTR protein in primary human bronchial epithelial cultures and other cell lines harboring the F508del-CFTR mutation to increase the quantity, stability, and function of F508del-CFTR at the cell surface, resulting in increased chloride ion transport. However, in vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.

ORKAMBI Market Forecast Report Scope

The ORKAMBI Market report provides insights into:

• A comprehensive product overview including the description, ORKAMBI Mechanism of Action, dosage and administration, research and development activities in cystic fibrosis.
• Elaborated details on ORKAMBI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ORKAMBI research and development activities in cystic fibrosis across the United States and Europe.
• The report also covers the patents information with expiry timeline around ORKAMBI.
• The report contains forecasted ORKAMBI Sales for cystic fibrosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for cystic fibrosis.
• The ORKAMBI Market Size Report also features the SWOT analysis with analyst views for ORKAMBI in cystic fibrosis.

ORKAMBI Methodology

The ORKAMBI Market Size Report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and ORKAMBI Sales Data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ORKAMBI Market Analytical Perspective by DelveInsight

• In-depth ORKAMBI Market Assessment

This report provides a detailed market assessment of ORKAMBI for cystic fibrosis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan. This segment of the report provides forecasted ORKAMBI Sales Data from 2023 to 2032.

• ORKAMBI Clinical Trials Assessment

The report provides the ORKAMBI Clinical Trials information for cystic fibrosis covering trial interventions, trial conditions, trial status, start and completion dates.

ORKAMBI Market Forecast Report Highlights 

• In the coming years, the market scenario for cystic fibrosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug ORKAMBI manufacturers to penetrate more into the market.  
• The ORKAMBI Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ORKAMBI dominance.
• Other emerging products for cystic fibrosis are expected to give tough market competition to ORKAMBI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ORKAMBI in cystic fibrosis.
• Our in-depth analysis of the forecasted ORKAMBI Sales Data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ORKAMBI in cystic fibrosis.
• Analyze ORKAMBI Cost, pricing trends, and market positioning to support strategic decision-making in the Pridopidine Market Landscape.

Key Questions

• What is the product type, route of administration and ORKAMBI Mechanism of Action?
• What is the ORKAMBI Clinical Trials status of the study related to Cystic Fibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ORKAMBI development?
• What are the key designations that have been granted to ORKAMBI for cystic fibrosis?
• What is the forecasted market scenario of ORKAMBI for cystic fibrosis?
• What are the forecasted ORKAMBI Sales in the six major countries, including the United States and Europe (Germany, France, Italy, Spain, and the United Kingdom)? 
• What are the other emerging products available and how are these giving competition to ORKAMBI for cystic fibrosis?
• Which are the late-stage emerging therapies under development for the treatment of cystic fibrosis?

Stay updated with us for Recent Articles @ New DelveInsight Blogs